| 1 |
Smith DM, Agura E, Netto G, et al. Liver transplant-associated graft-versus-host disease[J]. Transplantation, 2003, 75(1): 118-126.
|
| 2 |
Elsiesy H, Ibrahim A, Selim K, et al. Graft-versus-host disease after liver transplantation: A single-center case series[J]. Ann Transplant, 2015, 20: 397-401.
|
| 3 |
Murali AR, Chandra S, Stewart Z, et al. Graft versus host disease after liver transplantation in adults: A case series, review of literature, and an approach to management[J]. Transplantation, 2016, 100(12): 2661-2670.
|
| 4 |
Kang WH, Hwang S, Song GW, et al. Acute graft-vs-host disease after liver transplantation: Experience at a high-volume liver transplantation center in Korea[J]. Transplant Proc, 2016, 48(10): 3368-3372.
|
| 5 |
Moroso V, Metselaar HJ, Mancham S, et al. Liver grafts contain a unique subset of natural killer cells that are transferred into the recipient after liver transplantation[J]. Liver Transpl, 2010, 16(7): 895-908.
|
| 6 |
Yu E, Ueta H, Kimura H, et al. Graft-versus-host disease following liver transplantation: Development of a high-incidence rat model and a selective prevention method[J]. Am J Transplant, 2017, 17(4):979-991.
|
| 7 |
Taylor AL, Gibbs P, Sudhindran S, et al. Monitoring systemic donor lymphocyte macrochimerism to aid the diagnosis of graft-versus-host disease after liver transplantation[J]. Transplantation, 2004, 77(3): 441-446.
|
| 8 |
Ono R, Watanabe T, Kawakami E, et al. Co-activation of macrophages and T cells contribute to chronic GVHD in human IL-6 transgenic humanised mouse model[J]. EBioMedicine, 2019. [Epub ahead of print]
|
| 9 |
Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy[J]. Nat Rev Immunol, 2012, 12(6): 443-458.
|
| 10 |
Nassereddine S, Rafei H, Elbahesh E, et al. Acute graft versus host disease: A comprehensive review[J]. Anticancer Res, 2017, 37(4): 1547-1555.
|
| 11 |
Riesner K, Shi Y, Jacobi A, et al. Initiation of acute graft-versus-host disease by angiogenesis[J]. Blood, 2017, 129(14): 2021-2032.
|
| 12 |
Schwab L, Goroncy L, Palaniyandi S, et al. Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage[J]. Nat Med, 2014, 20(6): 648-654.
|
| 13 |
Klämbt V, Wohlfeil SA, Schwab L, et al. A novel function for P2Y2 in myeloid recipient-derived cells during graft-versus-host disease[J]. J Immunol, 2015, 195(12): 5795-5804.
|
| 14 |
Socié G, Mary JY, Lemann M, et al. Prognostic value of apoptotic cells and infiltrating neutrophils in graft-versus-host disease of the gastrointestinal tract in humans: TNF and Fas expression[J]. Blood, 2004, 103(1): 50-57.
|
| 15 |
Martin PJ. Pathogenic neutrophils in acute GVHD[J]. Blood, 2018, 131(16): 1774-1775.
|
| 16 |
Hülsdünker J, Ottmüller KJ, Neeff HP, et al. Neutrophils provide cellular communication between ileum and mesenteric lymph nodes at graft-versus-host disease onset[J]. Blood, 2018, 131(16): 1858-1869.
|
| 17 |
Stickel N, Hanke K, Marschner D, et al. MicroRNA-146a reduces MHC-Ⅱ expression via targeting JAK/STAT-signaling in dendritic cells after stem cell transplantation[J]. Leukemia, 2017, 31(12):2732-2741.
|
| 18 |
Chen X, Vodanovic-Jankovic S, Johnson B, et al. Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease[J]. Blood, 2007, 110(10): 3804-3813.
|
| 19 |
Beres AJ, Drobyski WR. The role of regulatory T cells in the biology of graft versus host disease[J]. Front Immunol, 2013, 4: 163.
|
| 20 |
Robb RJ, Lineburg KE, Kuns RD, et al. Identification and expansion of highly suppressive CD8＋FoxP3＋ regulatory T cells after experimental allogeneic bone marrow transplantation[J]. Blood, 2015, 119(24): 5898-5908.
|
| 21 |
Chan EY, Larson AM, Gernsheimer TB, et al. Recipient and donor factors influence the incidence of graft-vs.-host disease in liver transplant patients[J]. Liver Transpl, 2010, 13(4): 516-522.
|
| 22 |
Uchiyama H, Kayashima H, Matono R, et al. Relevance of HLA compatibility in living donor liver transplantation: the double-edged sword associated with the patient outcome[J]. Clin Transplant, 2012, 26(5): E522-E529.
|
| 23 |
Kamei H, Oike F, Fujimoto Y, et al. Fatal graft-versus-host disease after living donor liver transplantation: differential impact of donor-dominant one-way HLA matching[J]. Liver Transpl, 2006, 12(1): 140-145.
|
| 24 |
Soejima Y, Shimada M, Suehiro T, et al. Graft-versus-host disease following living donor liver transplantation[J]. Liver Transpl, 2004, 10(3): 460-464.
|
| 25 |
Shimata K, Sakamoto R, Anan T, et al. Fatal graft-versus-host disease after living-donor liver transplantation from an HLA-DR-mismatched donor[J]. Pediatr Transplant, 2017, 21(Suppl 1): e13039.
|
| 26 |
Elfeki MA, Pungpapong S, Genco PV, et al. Graft-versus-host disease after orthotopic liver transplantation: multivariate analysis of risk factors[J]. Clin Transplant, 2016, 29(12): 1063-1066.
|
| 27 |
Akbulut S, Yilmaz M, Yilmaz S. Graft-versus-host disease after liver transplantation：A comprehensive literature review[J]. World J Gastroenterol, 2012, 18(37): 5240-5248.
|
| 28 |
Yuksekkaya HA, Arikan C, Tumgor G, et al. Late-onset graft-versus-host disease after pediatric living-related liver transplantation for Langerhans cell histiocytosis[J]. Pediatr Transplant, 2011, 15(6): E105-E109.
|
| 29 |
Kohler S, Pascher A, Junge G, et al. Graft versus host disease after liver transplantation–a single center experience and review of literature[J]. Transpl Int, 2008, 21(5): 441-451.
|
| 30 |
Meenakshi S, Chawla YK, Arora SK. Immunology of hepatocellular carcinoma[J]. World J Hepatol, 2015, 7(17): 2080-2090.
|
| 31 |
Xie S, Tang LG, Cai X, et al. Might liver transplantation recipients with primary hepatocellular carcinoma benefit from GVT effect of aGVHD？[J]. Chinese-German J Clin Oncol, 2014, 13 (11): 535-538.
|
| 32 |
Meng XQ, Chen XH, Sahebally Z, et al. Cytokines are early diagnostic biomarkers of graft-versus-host disease in liver recipients[J]. Hepatobiliary Pancreat Dis Int, 2017, 16(1): 45-51.
|
| 33 |
Kim GY, Schmelkin LA, Davis MDP, et al. Dermatologic manifestations of solid organ transplantation-associated graft-versus-host disease: A systematic review[J]. J Am Acad Dermatol, 2017, 78(6): 1097-1101.
|
| 34 |
Strong Rodrigues K, Oliveira-Ribeiro C, de Abreu Fiuza Gomes S, et al. Cutaneous graft-versus-host disease: Diagnosis and treatment[J]. Am J Clin Dermatol, 2018, 19(1):33-50.
|
| 35 |
Taylor AL, Gibbs P, Bradley JA. Acute graft versus host disease following liver transplantation: the enemy within[J]. Am J Transplant, 2015, 4(4): 466-474.
|
| 36 |
Knox KS, Behnia M, Smith LR, et al. Acute graft-versus-host disease of the lung after liver transplantation[J]. Liver Transpl, 2002, 8(10): 968-971.
|
| 37 |
Padovan CS, Gerbitz A, Sostak P, et al. Cerebral involvement in graft-versus-host disease after murine bone marrow transplantation[J]. Neurology, 2001, 56(8): 1106-1108.
|
| 38 |
Triulzi DJ, Nalesnik MA. Microchimerism, GVHD, and tolerance in solid organ transplantation[J]. Transfusion, 2010, 41(3): 419-426.
|
| 39 |
Meves A, el-Azhary RA, Talwalkar JA, et al. Acute graft-versus-host disease after liver transplantation diagnosed by fluorescent in situ hybridization testing of skin biopsy specimens[J]. J Am Acad Dermatol, 2006, 55(4): 642-646.
|
| 40 |
Rogulj IM, Deeg J, Lee SJ. Acute graft versus host disease after orthotopic liver transplantation[J]. J Hematol Oncol, 2012, 5(1): 50-50.
|
| 41 |
Grubic Z, Stingl K, Cecuk Jelicic E, et al. Repetitive DNA polymorphisms in following chimerism after allogeneic bone marrow transplantation[J]. Clin Transplant, 2010, 19(5): 586-590.
|
| 42 |
Ferrara JL, Levine JE, Reddy P, et al. Graft-versus-host disease[J]. Lancet, 2009, 373(9674): 1550-1561.
|
| 43 |
Vander Lugt MT, Braun TM, Hanash S, et al. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death[J]. N Engl J Med, 2013, 369(6): 529-539.
|
| 44 |
Hartwell MJ, Özbek U, Holler E, et al. An early-biomarker algorithm predicts lethal graft-versus-host disease and survival[J]. Jci Insight, 2017, 2(3): e89798.
|
| 45 |
Zitzer NC, Garzon R, Ranganathan P. Toll-like receptor stimulation by microRNAs in acute graft-vs.-host disease[J]. Front Immunol, 2018, 9:2561
|
| 46 |
Perri R, Assi M, Talwalkar J, et al. Graft vs. host disease after liver transplantation: a new approach is needed[J]. Liver Transpl, 2010, 13(8): 1092-1099.
|
| 47 |
Ali R, Ramdial J, Algaze S, et al. The role of anti-thymocyte globulin or alemtuzumab-based serotherapy in the prophylaxis and management of graft-versus-host disease[J]. Biomedicines, 2017, 5(4):E67.
|
| 48 |
Elfeki MA, Genco PV, Pungpapong S, et al. Abatacept use in graft-versus-host disease after orthotopic liver transplantation: a case report[J]. Transplant Proc, 2014, 46(7): 2422-2425.
|
| 49 |
Lehner F, Becker T, Sybrecht L, et al. Successful outcome of acute graft-versus-host disease in a liver allograft recipient by withdrawal of immunosuppression[J]. Transplantation, 2002, 73(2): 307-310.
|
| 50 |
Yashar S, Wu SS, Binder SW, et al. Acute graft-versus-host disease after pediatric solid organ transplant[J]. J Drugs Dermato, 2008, 7(5): 467-469.
|
| 51 |
Sudhindran S, Taylor A, Delriviere L, et al. Treatment of graft-versus-host disease after liver transplantation with basiliximab followed by bowel resection[J]. Am J Transplant, 2003, 3(8):1024-1029.
|
| 52 |
Rai V, Dietz NE, Agrawal DK. Immunological basis for treatment of graft versus host disease after liver transplant[J]. Expert Rev Clin Immunol, 2016, 12(5): 583-593.
|
| 53 |
Levine JE. Implications of TNF-α in the pathogenesis and management of GVHD[J]. Int J Hematol, 2011, 93(5): 571-577.
|
| 54 |
Yang J, Cheuk DK, Ha SY, et al. Infliximab for steroid refractory or dependent gastrointestinal acute graft-versus-host disease in children after allogeneic hematopoietic stem cell transplantation[J]. Pediatr Transplant, 2012, 16(7): 771-778.
|
| 55 |
Byrne JL, Stainer C, Cull G, et al. The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia[J]. Bone Marrow Transplant, 2000, 25(4): 411-417.
|
| 56 |
Kumar A, Reljic T, Hamadani M, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis: an updated systematic review and meta-analysis[J]. Bone Marrow Transplant, 2018. [Epub ahead of print]
|
| 57 |
van der Zwan M, Baan CC, van Gelder T, et al. Review of the clinical pharmacokinetics and pharmacodynamics of alemtuzumab and its use in kidney transplantation[J]. Clin Pharmacokinet, 2018, 57(2): 191-207.
|
| 58 |
Solomon SR, Sizemore CA, Ridgeway M, et al. Safety and efficacy of rituximab-based first line treatment of chronic GVHD[J]. Bone Marrow Transplant, 2018. [Epub ahead of print]
|
| 59 |
Heaton ND, Reece AS, Tan KC. Graft-versus-host disease following liver transplantation[J]. J R Soc Med, 1992, 85(6): 313-314.
|
| 60 |
Nemoto T, Kubota K, Kita J, et al. Unusual onset of chronic graft-versus-host disease after adult living-related liver transplantation from a homozygous donor[J]. Transplantation, 2003, 75(5): 733-736.
|
| 61 |
Kakihana K, Fujioka Y, Suda W, et al. Fecal microbiota transplantation for patients with steroid-resistant/dependent acute graft-versus-host disease of the gut[J]. Blood, 2016, 128(16): 2083-2088.
|